ClinicalTrials.gg
CompletedNCT01010932Updated Jun 16, 2016Results posted

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

A Phase 3 interventional study of Dotarem and TOF MRA in Cerebral Arterial Diseases, sponsored by Guerbet. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-16.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
222
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.

Read the detailed description

Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.

02

Conditions studied

  • Cerebral Arterial Diseases

Keywords

  • carotid or vertebral artery disease
  • Contrast agent
  • MRA
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged more than 18 years
  • Strongly suspected of having carotid or vertebral arterial disease
  • Scheduled (or to be scheduled) to undergo computed tomography angiography (CTA) examination

Exclusion criteria

Exclusion Criteria:

  • Known grade IV or V chronic kidney disease (\<30 mL/min/1.73m²)
  • to MRI
  • Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    Dotarem and TOF MRA

    Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.

    Drug: Dotarem · Other: TOF MRA

Interventions

  • Each subject will receive one injection of Dotarem 0.2ml/kg

    Also known as: Gadoterate meglumine

  • OtherTOF MRA

    Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)

06

What researchers measure

Primary outcomes

  1. Technical Failure Rate

    Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-060).

    Time frame: 2 - 28 days

  2. Sensitivity

    Rate of true stenotic segments (i.e. with stenosis \>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).

    Time frame: 2-42 days

  3. Specificity

    Rate of true non-stenotic segments (i.e. without stenosis \>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).

    Time frame: 2 - 42 days

07

Results

Posted Aug 25, 2015

Participant flow

First patient first visit: 21 Sep 2009. Last patient last visit: 18 Nov 2010. Location: radiology departments

Participant flow — Overall Study
MilestoneTOF MRA Followed by Dotarem-enhanced MRA
Started222
Completed200
Not completed22

Outcome measures

PrimaryTechnical Failure Rate

Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-060).

Time frame:
2 - 28 days
Reported as:
Number · percentage of arterial segments
Technical Failure Rate
percentage of arterial segmentsDotarem-enhanced MRATOF MRA
Reader 14.65 (3.87 to 5.44)29.44 (27.74 to 31.13)
Reader 21.77 (1.28 to 2.26)16.70 (15.31 to 18.09)
Reader 32.20 (1.65 to 2.75)18.54 (17.10 to 19.99)
PrimarySensitivity

Rate of true stenotic segments (i.e. with stenosis \>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).

Time frame:
2-42 days
Reported as:
Number · percentage of stenotic segments
Sensitivity
percentage of stenotic segmentsDotarem-enhanced MRATOF MRA
Reader 158.46 (46.48 to 70.44)53.85 (41.73 to 65.97)
Reader 263.08 (51.34 to 74.81)63.08 (51.34 to 74.81)
Reader 353.85 (41.73 to 65.97)49.23 (37.08 to 61.38)
PrimarySpecificity

Rate of true non-stenotic segments (i.e. without stenosis \>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).

Time frame:
2 - 42 days
Reported as:
Number · percentage of non-stenotic segments
Specificity
percentage of non-stenotic segmentsDotarem-enhanced MRATOF MRA
Reader 198.13 (97.61 to 98.65)85.43 (84.07 to 86.78)
Reader 298.51 (98.05 to 98.98)90.39 (89.26 to 91.51)
Reader 398.63 (98.18 to 99.07)90.42 (89.30 to 91.55)

Adverse events

Collected over Adverse events were collected since the patient signing the patient consent form till the end of the last visits, maximum duration is 42 days.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dotarem MRA—1/200 (0.5%)12/200 (6%)
TOF MRA—0/200 (0%)0/200 (0%)
Computerized Tomography Angiography (CTA)—2/200 (1%)7/200 (3.5%)
Patients Discontinued Without Dotarem Administration—1/22 (4.5%)2/22 (9.1%)
Most frequent serious events
Most frequent serious events
EventDotarem MRATOF MRAComputerized Tomography Angiography (CTA)Patients Discontinued Without Dotarem Administration
Renal FailureRenal and urinary disorders0/2000/2000/2001/22
Carotid artery stenosisNervous system disorders1/2000/2000/2000/22
Chest PainGeneral disorders0/2000/2001/2000/22
CholelithiasisHepatobiliary disorders0/2000/2001/2000/22
Most frequent other events
Most frequent other events
EventDotarem MRATOF MRAComputerized Tomography Angiography (CTA)Patients Discontinued Without Dotarem Administration
Neutrophil Count increasedInvestigations0/2000/2001/2001/22
LymphopeniaInvestigations1/2000/2001/2001/22
Transient Ischemic AttackNervous system disorders0/2000/2000/2001/22
NauseaGastrointestinal disorders3/2000/2000/2000/22
HypertensionVascular disorders3/2000/2002/2000/22
HeadacheNervous system disorders0/2000/2003/2000/22
Injection site hematomaGeneral disorders2/2000/2001/2000/22
Alanine aminotransferase increasedInvestigations2/2000/2000/2000/22
DizzinessNervous system disorders2/2000/2001/2000/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TOF MRA Followed by Dotarem-enhanced MRA
<=18 years0
Between 18 and 65 years108
>=65 years114
Age, Continuous
Age, Continuous(years)TOF MRA Followed by Dotarem-enhanced MRA
Mean64.8 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)TOF MRA Followed by Dotarem-enhanced MRA
Female105
Male117
Region of Enrollment
Region of Enrollment(participants)TOF MRA Followed by Dotarem-enhanced MRA
United States81
Colombia35
Argentina48
Mexico18
Korea, Republic of39
Chile1
08

Study locations

1 site
  • Guerbet LLC
    Bloomington, Indiana 47403, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 4 years 8 months after primary completion. A results delay was requested in Nov 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2009
First posted
Nov 10, 2009
Start
Oct 2009
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results delay requested
Nov 9, 2012
Results first posted
Aug 25, 2015
Last update
Jun 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01010932
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Nov 10, 2009
Start date
Oct 2009
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Aug 25, 2015
Last update
Jun 16, 2016

Study contacts

Pierre DESCHE, MD
study director · Guerbet

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoterate meglumine

Start the discussion